



Mike Braun, Governor
State of Indiana

Indiana Family and Social Services Administration
Office of Medicaid Policy and Planning

402 W. WASHINGTON ST., ROOM W374, MS07
INDIANAPOLIS, IN 46204

MEETING AGENDA AND PUBLIC NOTIFICATION

Therapeutics Committee
June 12, 2026
9:00 A.M. EST

Hybrid Meeting

Indiana State Government Center South
Conference Room A
Virtual Meeting Information Below

1. Call to Order-Chair
2. Opening Comments-OMPP
3. Approval of Memoranda, Meeting of March 13, 2026
4. Preferred Drug List: Therapeutic Class Re-Review
 - a) Respiratory
 - i. Antihistamine-Decongestant Combinations/2nd Generation Antihistamines
 - ii. Beta Adrenergics and Corticosteroids
 - iii. Beta Agonists
 - iv. Bronchodilator Agents - Beta Adrenergic and Anticholinergic Combinations
 - v. Leukotriene Receptor Antagonists
 - vi. Nasal Antihistamines/Nasal Anti-Inflammatory Steroids
 - vii. Oral Inhaled Glucocorticoids
 - viii. Pulmonary Antihypertensives
 - ix. Respiratory and Allergy Biologics



- b) Anti-Infectives
 - i. Antivirals - Anti-Herpetic Agents
 - ii. Antivirals - Influenza & COVID-19 Agents
 - iii. Cephalosporins - 3rd Generation
 - iv. Fluoroquinolones
 - v. Hepatitis C Agents
 - vi. Macrolides
 - vii. Ophthalmic Antibiotics
 - viii. Ophthalmic Antibiotics/Corticosteroid Combinations
 - ix. Otic Antibiotics
 - x. Systemic Antifungals
 - xi. Topical Antifungals
 - xii. Topical Antivirals
 - xiii. Vaginal Antimicrobials
 - c) Cardiovascular
 - i. Angiotensin-Converting Enzyme (ACE) Inhibitors
 - ii. ACE Inhibitor Combinations
 - iii. Angiotensin II Receptor Antagonists (ARBs)
 - iv. ARB Combinations
 - v. Beta Adrenergic Blockers
 - vi. Beta Adrenergic Blockers with Diuretics
 - vii. Calcium Channel Blockers (CCBs)
 - viii. Miscellaneous Cardiac Agents
 - d) Lipotropics
 - i. Bile Acid Sequestrants
 - ii. Fibric Acid Derivatives
 - iii. HMG-CoA Reductase Inhibitors
 - iv. Lipotropics
 - e) Antimigraine Agents
 - f) Electrolyte Depleters
 - g) Multiple Sclerosis Agents
-

- h) Targeted Immunomodulators
- i) CNS and Others
 - i. Mental Health Agents
 - 1. Anti-Anxiety and Related Disorders
 - 2. Antidepressant Agents
 - 3. Antipsychotic and Antimanic Agents
 - 4. Alzheimer's and Dementia Agents
 - 5. Insomnia Agents
 - 6. Narcolepsy and Cataplexy Agents
 - 7. Non-Stimulant ADHD Agents
 - 8. Stimulants
- j) Drug Classes for SUPDL Consideration
 - i. Blood Factor Agents
 - ii. Cystinosis Agents
 - iii. Gaucher's Disease Agents
 - iv. Phenylketonuria Agents
 - v. Transthyretin Impacting Agents
- 5. New Business
- 6. Public Comment
- 7. Other Business
- 8. Adjourn

Microsoft Teams [Need help?](#)

[Join the meeting now](#)

Meeting ID: 280 026 277 044 5

Passcode: dw7iw7AN

Dial in by phone

[+1 952-222-7450,,776755444#](#) United States, Minneapolis

[Find a local number](#)

Phone conference ID: 776 755 444#

Join on a video conferencing device

Tenant key: teams@optum.onpexip.com

Video ID: 112 405 134 72

[More info](#)
